Search Results
Your search for texas a matches 2595 pages
Showing 1551 - 1600Expert Point of View: John V. Heymach, MD, PhD
“This is a watershed moment in the treatment of anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Often studies show only incremental improvements with a new treatment. This is different. Alectinib [Alecensa] shows a dramatic increase in efficacy that is also accompanied ...
ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers in Colorectal Cancer
As reported in the Journal of Clinical Oncology by Antonia R. Sepulveda, MD, PhD, of Columbia University, and colleagues, a joint guideline on the use of molecular biomarkers for evaluation of colorectal cancer has been developed by an expert panel from the American Society for Clinical Pathology...
Expert Point of View: Sumanta Kumar Pal, MD and John V. Heymach, MD, PhD
ASCO spokespersons at the press briefing lauded the results with larotrectinib and called for broader testing for tropomyosin receptor kinase fusions. The data for larotrectinib “bring us into a new era where treatment is truly based on mutation, not location,” said Sumanta Kumar Pal, MD, a...
Expert Point of View: Cathy Eng, MD, FACP and Alfred Neugut, MD, PhD
Cathy Eng, MD, FACP, the Sophie Caroline Steves Distinguished Professor in Cancer Research at The University of Texas MD Anderson Cancer Center, Houston, said the trial demonstrates “the challenge of analyzing six individually conducted studies in a pooled analysis.” The study’s “potential...
Some Patients With Stage III Low-Risk Colon Cancer May Require Less Oxaliplatin Therapy
Patients with stage III colon cancer considered at low risk for recurrence may be treated effectively—and incur less neurotoxicity—with 3 months of an oxaliplatin-based regimen as compared with the standard 6 months, according to the results of the International Duration Evaluation of Adjuvant...
First Analysis of AACR Project GENIE Data Published
The first analysis of nearly 19,000 de-identified genomic records from the American Association for Cancer Research (AACR) international data-sharing initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) was recently published in Cancer Discovery. In addition to ...
Anthracyclines in HER2-Negative Breast Cancer
As reported by Joanne L. Blum, MD, PhD, of Baylor University Medical Center, Texas Oncology, and colleagues in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane ...
Venetoclax Achieves Durable and Deep Remissions in CLL
Preliminary study results suggest that venetoclax (Venclexta) plus rituximab (Rituxan) is a highly active combination in relapsed/refractory chronic lymphocytic leukemia (CLL), achieving durable responses and minimal residual disease negativity in previously treated patients. “The results of our...
Making American Research Great Again
In the past 10 years, we have made remarkable advances in how we fight cancer. One of the most powerful new tools in our arsenal is cancer immunotherapy, which reawakens our own immune system to produce stunning results for many suffering from advanced cancer. Immunotherapy saved President Jimmy...
ASCO 2017: Higher Gut Bacteria Diversity Tied to Slower Metastatic Melanoma Progression
The blend of bacteria in the digestive tract of metastatic melanoma patients is associated with disease progression or delay in patients treated with immunotherapy, reported Wargo et al at the 2017 ASCO Annual Meeting (Abstract 3008). Their study of fecal samples from 105 patients treated with...
ASCO's TAPUR Study Continues Its Expansion of Sites, Participants, and Collaborators
ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility. “We are very pleased with the...
Elizabeth J. Shpall, MD, and Nina Shah, MD—Mentor and Mentee: A Conversation
Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and recipient of the 2017 Women Who Conquer Cancer Mentorship Award, discusses promoting women in oncology with Nina Shah, MD, of the University of California, San Francisco, the protégé who nominated Dr. Shpall for this ...
Twitter Use at the ASCO Annual Meeting
As reported by Pemmaraju et al in the Journal of Oncology Practice, use of Twitter at the ASCO Annual Meeting has increased dramatically between 2011 and 2016. The investigators conducted a retrospective review of publicly available tweets collected by Nephrology On-Demand Analytics for the ASCO...
Image-Guided Biopsies Accurately Identify Patients With Breast Cancer Who Achieve Pathologic Complete Response Following Neoadjuvant Therapy
In a clinical feasibility trial conducted at The University of Texas MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved pathologic complete response after neoadjuvant systemic therapy consisting of chemotherapy and/or targeted therapy. Should the...
Study Finds Hypofractionated Whole-Breast Irradiation Leads Breast Cancer Radiation Therapies in Cost-Effectiveness, Quality of Life
In a study of three radiation therapies for early-stage breast cancer, one treatment option stands out as offering the most value based on factors including health outcomes, cost-effectiveness, and quality of life. The treatment—hypofractionated whole-breast irradiation—also requires...
After Nearly 4 Decades of Research, W.K. Alfred Yung, MD, Sees a New Era Ahead for Advances in Brain Tumors
After he was not accepted into the University of Hong Kong, plan B for W.K. Alfred Yung, MD, was to leave his country and immigrate to the United States to attend the University of Minnesota in Minneapolis—a move he considers more exile than choice. Born on April 8, 1948, in Hong Kong, Dr. Yung...
SU2C Awards Innovative Research Grants in Immuno-oncology to 10 Early-Career Scientists
Stand Up to Cancer (SU2C) has announced the award of $7.5 million in Innovative Research Grants focused on immuno-oncology to 10 early-career scientists, in a program funded by a grant from Bristol-Myers Squibb Company (BMS), an SU2C Visionary Supporter. These awards were announced at the 2017...
Susan G. Komen Names Eight Advisors to Guide Breast Cancer Research Program
Susan G. Komen announced new advisory roles for eight leaders in breast cancer who will guide the organization’s education and advocacy work, public health efforts, and help direct Komen’s $920 million research program. On April 1, Jennifer A. Pietenpol, PhD, of Vanderbilt-Ingram Cancer Center,...
Zoledronic Acid Every 12 Weeks Noninferior to Every 4 Weeks in Skeletal-Related Event Rate for Breast Cancer With Bone Metastases
In the phase III OPTIMIZE-2 trial reported in JAMA Oncology, Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, and colleagues found that an every-12-week schedule of zoledronic acid was noninferior to an every-4-week schedule with regard to skeletal-related event...
Tackling the Obesity and Cancer Epidemic
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining...
James Allison, PhD, Named One of TIME ’s 100 Most Influential People in 2017
The University of Texas MD Anderson Cancer Center Chair of Immunology, James Allison, PhD—whose pivotal insight to attack cancer by treating the immune system instead of the tumor revived cancer immunotherapy—has been named to the 2017 TIME 100 Most Influential People. His approach launched a...
Anticipate Sexual Dysfunction in Patients on Aromatase Inhibitors
For patients with breast cancer starting on aromatase inhibitors, sexual dysfunction is commonly reported. Early intervention may lessen its impact—but it’s not an easy fix, says a specialist in this area, Leslie R. Schover, PhD. Dr. Schover is Founder of Will2Love, an online sexual health program ...
Triple‑Modality Therapy Achieves Good Control in Inflammatory Breast Cancer
Contemporary triple-modality therapy achieves excellent locoregional tumor control of inflammatory breast cancer, with only 4 locoregional recurrences out of 114 patients treated at The University of Texas MD Anderson Cancer Center, Houston. The investigators described their approach at the...
Texas Medical Center Names William F. McKeon President and CEO
The Texas Medical Center (TMC) has announced that its Board of Directors has appointed William F. McKeon as President and Chief Executive Officer (CEO) and member of the Board of Directors. Mr. McKeon previously held the position of Executive Vice President, Chief Strategy and Operating Officer....
Rates of Oral HPV Infection Plummet After Vaccination
Vaccination against the human papillomavirus (HPV) reduced the risk of acquiring oral HPV infections by 88%, in one of the first large studies to explore vaccination’s impact in the oropharynx. The study will be presented at the 2017 ASCO Annual Meeting, and the findings were released in advance of ...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...
ASCO 2017: HPV Vaccination May Reduce Oral HPV Infections but Is Still Underutilized
In one of the first large studies to explore the possible impact of human papillomavirus (HPV) vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was...
Ensuring Equitable Cancer Care for All Patients
Cancer is the second-leading cause of death across the globe. Significant efforts, such as the National Cancer Moonshot Initiative and The University of Texas MD Anderson Cancer Center’s Moon Shots Program, will drive advances in cancer prevention, screening, and treatment. However, right now,...
Never Smokers Account for Increased Proportion of NSCLC Cases
In a retrospective study in three U.S. institutions reported in the Journal of the National Cancer Institute, Pelosof et al found that never smokers accounted for an increasing proportion of cases of non–small cell lung cancer (NSCLC) during the period from 1990 to 2013. Joan Schiller, MD, of the...
Cancer Research UK Awards Six U.S. Scientists $87 Million as Part of ‘Grand Challenge’
Cancer Research UK has announced that six leading American scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research. The initial $87 million “Grand Challenge” fund will be distributed across 4 international teams of academics from 6...
Hyperthermic Intraperitoneal Chemoperfusion May Be Efficacious for Peritoneal Metastases
Hyperthermic intraperitoneal chemoperfusion is efficacious when used as part of multimodality therapy for low-volume peritoneal metastases of gastric cancer, suggests a prospective single-arm phase II trial.1 Among the 19 patients enrolled, all of whom had stage IV disease with either...
PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma
According to a study by Skinner et al, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squamous cell carcinoma is sensitive to radiation, HPV-negative tumors are...
Adding Bevacizumab to Paclitaxel-Carboplatin in Recurrent Platinum-Sensitive Ovarian Cancer
In a phase III trial (NRG Oncology/Gynecologic Oncology Group GOG-0213 trial) reported in The Lancet Oncology, Coleman et al found evidence of an overall survival advantage with the addition of bevacizumab (Avastin) to paclitaxel-carboplatin in recurrent platinum-sensitive ovarian cancer. The...
Cancer Mortality Trends in the United States Vary Widely by County From 1980 to 2014
In a study reported in JAMA, Ali H. Mokdad, PhD, and colleagues from the University of Washington, Seattle, found that cancer mortality rates in the United States dropped from 240.2 to 192.0 per 100,000 population between 1980 and 2014.1 Mortality rates varied widely among U.S. counties for...
Higher Costs for Complex Cancer Surgery May Be an Indicator of Lower-Quality Care
Higher costs for complex cancer surgery may be an indicator of worse—rather than better—quality of care, according to new research by experts at Rice University and The University of Texas MD Anderson Cancer Center. Their findings are published by Ho et al in Surgery, and provide...
Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...
Neoadjuvant Chemotherapy for Breast Cancer and Risk for Local Metastases
A pathologic complete response to presurgical therapy occurs in between 40% and 50% of patients with HER2-positive and triple-negative breast cancer, raising the question of the need for surgery for all patients after neoadjuvant chemotherapy indicates a pathologic complete response in...
Racial/Ethnic Disparities in End-of-Life Care for Patients With Ovarian Cancer
A study using linked Texas Cancer Registry–Medicare data has identified racial/ethnic disparities in end-of-life care in women with ovarian cancer. The study was reported by Taylor et al in the Journal of Clinical Oncology. Study Details The study included 3,666 patients dying in 2000 to...
Efficacy Analysis of ABC Breast Cancer Trials of Adjuvant Taxane With/Without Anthracycline in HER2-Negative Disease
As reported by Blum et al in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane plus doxorubicin/cyclophosphamide (TaxAC) regimens vs six cycles of...
NCCN Foundation Board of Directors Names New Leadership
The NCCN Foundation® has named Gena Cook, Cofounder and Chief Executive Officer of Navigating Cancer, as Chair of the National Comprehensive Cancer Network® (NCCN®) Foundation Board of Directors. Ms. Cook, who was elected to the Board in 2010, succeeds Ellen O. Tauscher, former U.S....
Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer
Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...
Research Reveals New Treatment Possibilities for Prostate Cancer
Not all cancer research will result in a positive outcome for patients, but all research does provide information that continues to advance the treatment of cancer care. Recent clinical trials, including one funded in part by the Conquer Cancer Foundation (CCF) of ASCO, show that most prostate...
W.E. ‘Ed’ Bosarge, Jr, PhD, Honored With 2017 AACR Distinguished Public Service Award
The American Association for Cancer Research (AACR) presented an AACR Distinguished Public Service Award to W.E. “Ed” Bosarge, Jr, PhD, in honor of his generous, unstinting contributions to cancer research, innovative medical and environmental science, and the AACR. Dr. Bosarge is known for his...
New ASTRO Guideline Establishes Standard of Care for Curative Treatment of Oropharyngeal Cancer With Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has issued a new clinical guideline for the management of oropharyngeal cancer. The guideline, “Radiation therapy for oropharyngeal squamous cell carcinoma: An ASTRO Evidence-based Clinical Practice Guideline,” was published by Sher et ...
Breast Cancer Treatment Options Vary Widely in Cost-Effectiveness
A study published by Smith et al in the Journal of the National Cancer Institute indicates that different therapies for early-stage breast cancer have very different relative values. Some therapies may have fewer complications and be much less expensive than others. Women may be making treatment...
Thomas E. Starzl, MD, PhD, ‘Father of Modern Transplantation,’ Dies at Age 90
Scientific and clinical pioneers have one thing in common: they move beyond their comfort zone and take calculated risks. One such pioneer, whose calculated risks gave hope to otherwise hopelessly ill people, was Thomas E. Starzl, MD, PhD, who performed the world’s first successful liver...
Conquer Cancer Foundation Honors 65 Young Oncology Professionals With Merit Awards
The Conquer Cancer Foundation of ASCO (CCF) is pleased to announce the recipients of its 2017 CCF Merit Awards in Gastrointestinal Cancers, Cancer Survivorship, Genitourinary Cancers, Immuno-Oncology, and Quality Care. The following 65 young researchers, recognized for the scientific merit of their ...
AACR 2017: PRMT1 Identified as Potential Druggable Target for Pancreatic Cancer
A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma, according to results presented by Giuliani et al the 2017 Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC (Abstract 3016)....
AACR 2017: Minority Patients With Colorectal Cancer Report Higher Burden of Poor Quality-of-Life Than Whites
A study presented by Hildebrandt et al at the 2017 Annual Meeting of the American Association of Cancer Research (AACR; Abstract 990) revealed several findings about racial disparities in health-related quality of life among colorectal cancer patients. Hispanics and blacks had a higher burden of...
AACR 2017: Combination Immunotherapies Show Clinical Activity in Metastatic RCC in Pilot Study
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (RCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. The results of...
